- Report
- August 2026
- 171 Pages
Global
From €5254EUR$5,850USD£4,488GBP
- Report
- July 2026
- 108 Pages
Global
From €4266EUR$4,750USD£3,644GBP
- Report
- July 2026
- 118 Pages
Global
From €4266EUR$4,750USD£3,644GBP
- Report
- May 2026
- 400 Pages
Global
From €4445EUR$4,949USD£3,797GBP
- Report
- September 2025
- 150 Pages
Global
From €4356EUR$4,850USD£3,721GBP
- Report
- November 2025
- 150 Pages
Global
From €4356EUR$4,850USD£3,721GBP
- Report
- October 2025
- 150 Pages
Global
From €4356EUR$4,850USD£3,721GBP
- Report
- October 2025
- 90 Pages
Middle East
From €4042EUR$4,500USD£3,453GBP
- Report
- November 2023
- 337 Pages
Global
From €4786EUR$5,515USD£3,950GBP
- Report
- September 2023
- 310 Pages
Global
From €4786EUR$5,515USD£3,950GBP
- Report
- January 2020
- 508 Pages
Global
From €4400EUR$4,899USD£3,759GBP
- Report
- September 2024
- 154 Pages
Global
From €2021EUR$2,250USD£1,726GBP
- Report
- July 2023
- 300 Pages
Global
From €4446EUR$4,950USD£3,798GBP
- Report
- June 2024
- 295 Pages
Global
From €4446EUR$4,950USD£3,798GBP
- Report
- November 2024
- 100 Pages
Global
From €5344EUR$5,950USD£4,565GBP
- Report
- October 2023
- 200 Pages
Global
From €5344EUR$5,950USD£4,565GBP
- Report
- March 2024
- 180 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- January 2024
- 200 Pages
Global
From €3727EUR$4,150USD£3,184GBP
- Report
- April 2023
- 120 Pages
Global
From €4266EUR$4,750USD£3,644GBP
- Report
- June 2024
- 140 Pages
Middle East, Africa
From €3475EUR$3,869USD£2,968GBP

The Autologous Stem Cell market is a subset of the larger Stem Cell market. Autologous stem cells are those derived from the patient's own body, and are used to treat a variety of conditions, including degenerative diseases, autoimmune diseases, and tissue damage. Autologous stem cells are typically harvested from the patient's bone marrow, adipose tissue, or peripheral blood. The cells are then processed and expanded in the laboratory before being re-injected into the patient.
The Autologous Stem Cell market is growing rapidly, driven by advances in stem cell technology and the increasing availability of treatments. The market is expected to continue to expand as more treatments become available and the technology continues to improve.
Some companies in the Autologous Stem Cell market include Osiris Therapeutics, Inc., Athersys, Inc., Mesoblast Limited, and Pluristem Therapeutics, Inc. Show Less Read more